Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 441.00K | $ 1.92M | $ 18.05M | $ 5.40M | $ 6.70M |
| Gross Profit | $ -26.83M | $ 640.00K | $ 14.62M | $ 3.91M | $ 6.40M |
| Operating Income | $ -68.51M | $ -23.44M | $ -37.44M | $ -82.13M | $ -26.95M |
| EBITDA | $ -68.51M | $ -27.95M | $ -37.29M | $ -80.50M | $ -45.45M |
| Net Income | $ -35.13M | $ -31.54M | $ -41.66M | $ -84.35M | $ -64.38M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 134.55M | $ 7.42M | $ 13.17M | $ 54.59M | $ 18.92M |
| Total Assets | $ 150.73M | $ 20.99M | $ 33.37M | $ 80.21M | $ 43.76M |
| Total Debt | $ 568.00K | $ 537.00K | $ 19.42M | $ 32.83M | $ 426.35K |
| Net Debt | $ -133.98M | $ -6.88M | $ 6.24M | $ -21.75M | $ -18.49M |
| Total Liabilities | $ 17.70M | $ 13.69M | $ 44.28M | $ 57.13M | $ 19.19M |
| Stockholders' Equity | $ 133.03M | $ 7.30M | $ -10.91M | $ 23.08M | $ 24.56M |
| Cash Flow | |||||
| Free Cash Flow | $ -49.06M | $ -30.84M | $ -26.85M | $ -71.00M | $ -40.60M |
| Operating Cash Flow | $ -49.06M | $ -30.68M | $ -26.75M | $ -70.89M | $ -40.54M |
| Investing Cash Flow | $ 356.00K | $ -133.00K | $ -95.00K | $ -113.00K | $ 11.13M |
| Financing Cash Flow | $ 175.85M | $ 25.04M | $ -14.70M | $ 106.76M | $ 44.78M |